Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carrie McGuire

Physician Assistant, Medical Guthrie, OK Physician Assistant

NPI 1104988138 CMS profile 11045071

2919 S Division St, Guthrie, OK 73044

Open in the dashboard

General payments

$4,985

306 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie McGuire of Guthrie, OK is reported in the CMS Open Payments database as having received $4,985 across 306 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,355 69
2024 General $809 54
2023 General $902 57
2022 General $769 48
2021 General $1,150 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie McGuire
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Carrie McGuire were reported at $1,355. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Carrie McGuire Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,150 $156 $41–$563 $132
2022 $769 $185 $55–$649 $149
2023 $902 $199 $58–$717 $160
2024 $809 $206 $62–$740 $164
2025 $1,355 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $727 44 payments
  2. Pfizer Inc. $529 44 payments
  3. GlaxoSmithKline, LLC. $506 41 payments
  4. Novo Nordisk Inc $453 31 payments
  5. AstraZeneca Pharmaceuticals LP $357 17 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $310 17 payments
  7. Lilly USA, LLC $213 12 payments
  8. Corium, Inc. $202 11 payments
  9. Astellas Pharma US Inc $169 7 payments
  10. Merck Sharp & Dohme Corporation $144 9 payments
  11. Other $1,375 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,985 306 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $401 34 payments
  2. Ozempic $320 22 payments
  3. TRINTELLIX $292 16 payments
  4. UBRELVY $270 19 payments
  5. RYBELSUS $267 18 payments
  6. QULIPTA $259 16 payments
  7. NURTEC ODT $250 22 payments
  8. FARXIGA $246 11 payments
  9. ZAVZPRET $225 19 payments
  10. COMIRNATY $220 19 payments
  11. Other $4,608 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

1,715

Median for Physician Assistant: 241

Drug cost

$233,816

Median for Physician Assistant: $4,110

Branded share of claims

13.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 11 $93,192
Ozempic Semaglutide Brand 44 $62,706
Mounjaro Tirzepatide Brand 13 $27,964
Eliquis Apixaban Brand 23 $18,846
Tresiba Flextouch U-100 Insulin Degludec Brand 19 $7,607
Cyclobenzaprine Hcl Generic 32 $1,864
Gabapentin Generic 67 $1,475
Albuterol Sulfate Hfa Albuterol Sulfate Brand 59 $1,349
Vilazodone Hcl Generic 11 $1,313
Omeprazole Generic 77 $1,252

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$30,389

Of which drugs: $1,601

Medicare patients

162

Average age 73

Services billed

795

94 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 57%
Chronic kidney disease 29%
Depression 29%
Ischemic heart disease 28%
Diabetes 25%
Osteoporosis 19%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 11 11 $890

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $107
$107 — —
Veozah
  • Astellas Pharma US Inc $81
$81 — —
MOUNJARO
  • Lilly USA, LLC $54
$54 13 —
GEMTESA
  • Sumitomo Pharma America, Inc. $44
$44 — —
RYBELSUS
  • Novo Nordisk Inc $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

306 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record